SCHEMBL4547585

SCHEMBL4547585

CCCCC[C@H](O)[C@H](O)/C=C/c1ccccc1[C@@H](O)CCCC(=O)OC

nearest known ligand 0.66

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.66
NFKB2 Q00653 2/20 0.66
RELA Q04206 2/20 0.66
FPR2 P25090 12/20 0.58
PPARG P37231 6/20 0.55
PPARA Q07869 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589185 1.00 NFKB1 (0.66) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL589186 1.00 NFKB1 (0.66) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL17402445 1.00 NFKB1 (0.66) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL15942746 1.00 NFKB1 (0.66) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL4547582 1.00 NFKB1 (0.66) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL589187 1.00 NFKB1 (0.66) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL18532079 0.92 NFKB1 (0.61) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL29564346 0.89 NFKB1 (0.65) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL590253 0.89 NFKB1 (0.65) NFKB1NFKB2RELAFPR2PPARG
SCHEMBL590254 0.89 NFKB1 (0.65) NFKB1NFKB2RELAFPR2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355562-A1 METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF ADA FORSYTH INSTITUTE, INC. 2023-11-09 US disclosed
US-20230355562-A1 METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF ADA FORSYTH INSTITUTE, INC. 2023-11-09 US disclosed
US-20200330551-A1 COMPOSITIONS AND METHODS OF TREATING CANCER USING LIPID AGONISTS AND RECEPTORS THEREOF ADA FORSYTH INSTITUTE, INC. 2020-10-22 US disclosed
US-20180078519-A1 Methods for Stabilizing Atherosclerotic Plaques Using Lipoxins, Resolvins, and Analogs Thereof THE FORSYTH INSTITUTE (US) 2018-03-22 US disclosed
US-20180078519-A1 Methods for Stabilizing Atherosclerotic Plaques Using Lipoxins, Resolvins, and Analogs Thereof THE FORSYTH INSTITUTE (US) 2018-03-22 US disclosed
US-20120114566-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2012-05-10 US disclosed
US-20120114566-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2012-05-10 US disclosed
US-8093417-B2 Lipoxin analogs and methods for the treatment of periodontal disease TRUSTEES OF BOSTON UNIVERSITY (US) 2012-01-10 US disclosed
US-8093417-B2 Lipoxin analogs and methods for the treatment of periodontal disease TRUSTEES OF BOSTON UNIVERSITY (US) 2012-01-10 US disclosed
US-20110064677-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2011-03-17 US disclosed
US-20110064677-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2011-03-17 US disclosed
US-7812054-B2 Lipoxin analogs and methods for the treatment of periodontal disease TRUSTEES OF BOSTON UNIVERSITY (US) 2010-10-12 US disclosed
US-7700650-B2 Lipoxin analogs and method for the treatment of periodontal disease TRUSTEES OF BOSTON UNIVERSITY (US) 2010-04-20 US disclosed
US-7700650-B2 Lipoxin analogs and method for the treatment of periodontal disease TRUSTEES OF BOSTON UNIVERSITY (US) 2010-04-20 US disclosed
US-20090311201-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE TRUSTEES OF BOSTON UNIVERSITY (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114566-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE ALOX5, ALOX15B, ALOX12 NFKB1 343/4885NFKB2 450/4885RELA 496/4885
US-20110064677-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE ALOX5, ALOX15B, ALOX12 NFKB1 343/4885NFKB2 450/4885RELA 496/4885
US-20090311201-A1 LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE ALOX5, ALOX15B, ALOX12 NFKB1 343/4885NFKB2 450/4885RELA 496/4885
US-20230355562-A1 METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF ALOX15B, ALOX15, ALOX5 NFKB1 1222/4885NFKB2 2037/4885RELA 2412/4885
US-20200330551-A1 COMPOSITIONS AND METHODS OF TREATING CANCER USING LIPID AGONISTS AND RECEPTORS THEREOF PLA2R1, LPAR1, LPAR5 NFKB1 1863/4885NFKB2 2026/4885RELA 1038/4885
US-20180078519-A1 Methods for Stabilizing Atherosclerotic Plaques Using Lipoxins, Resolvins, and Analogs Thereof ALOX15B, ALOX15, ALOX5 NFKB1 1222/4885NFKB2 2037/4885RELA 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.